Table 1.
AGPI (n=1,236) | AGPII (n=804) | |
---|---|---|
| ||
Diagnosis | ||
Autism | 1,134 (91.7) | 760 (94.5) |
ASD | 102 (8.3) | 44 (5.5) |
| ||
Gender | ||
Male | 990 (80.1) | 677 (84.2) |
Female | 246 (19.9) | 127 (15.8) |
| ||
Verbal/nonverbal status | ||
Verbal | 898 (72.6) | 553 (68.8) |
Nonverbal | 338 (27.4) | 251 (31.2) |
| ||
AGP site | ||
AGRE | 420 (34.0) | 46 (5.7) |
VANDERBILT | 16 (1.3) | 22 (2.7) |
IMGSAC | 330 (26.7) | 61 (7.6) |
DUKE | 50 (4.0) | 72 (9.0) |
CANAGEN | 80 (6.5) | 190 (23.6) |
INSERM | 22 (1.8) | 78 (9.7) |
STANFORD | 64 (5.2) | 0 (0) |
CPEA | 182 (14.7) | 22 (2.7) |
UNC | 58 (4.7) | 0 (0) |
MT. SINAI | 14 (1.1) | 0 (0) |
IRELAND | 0 (0) | 113 (14.1) |
PORTUGAL | 0 (0) | 200 (24.9) |
| ||
Family typeb | ||
Simplex | 0 (0) | 436 (54.2) |
Multiplex | 1,236 (100) | 223 (27.8) |
Unknown | 0 (0) | 145 (18.0) |
| ||
Ethnicity | ||
Caucasian | 1,036 (83.8) | 716 (89.1) |
Non-Caucasian | 200 (16.2) | 88 (10.9) |
| ||
Age at ADI-R assessment (month) | 101±39 | 96±44 |
Note: ADI-R = Autism Diagnostic Interview-Revised; AGP = Autism Genome Project; AGPI = patients from AGP phase I; AGPII = patients from AGP phase II; AGRE = Autism Genetics Resource Exchange; CANAGEN = Canadian Autism Genetics; CPEA = Collaborative Programs of Excellence in Autism; IMGSAC = International Molecular Genetic Study of Autism Consortium; INSERM = Institute National de la Santé et de la Recherche Médicale; UNC, University of North Carolina.
Values are count (percentage) or mean ± standard deviation.
For family type, multiplex Autism Genome Project (AGP) families were defined as having at least two individuals receiving autism spectrum disorder (ASD) diagnoses who were first to third degree relatives (for third degree, only considering cousins); simplex families as having only one known ASD individual with no family history of ASD in first to third (cousin) degree relatives.